Paclitaxel and Radiotherapy for High-Risk Endometrial Cancer
Author Information
Author(s): Mangili Giorgia, De Marzi Patrizia, Beatrice Saverio, Rabaiotti Emanuela, Viganò Riccardo, Frigerio Luigi, Gentile Cinzia, Fazio Ferruccio
Primary Institution: San Raffaele Hospital, Milan, Italy
Hypothesis
Does concomitant Paclitaxel and radiotherapy improve clinical outcomes in high-risk endometrial cancer patients?
Conclusion
The combination of pelvic radiotherapy and weekly Paclitaxel followed by consolidation chemotherapy appears to be an effective treatment for high-risk endometrial cancer patients.
Supporting Evidence
- Relapses occurred in five patients (21.7%) with a median time to recurrence of 18.6 months.
- Overall survival for patients who completed the treatment was 81%.
- All recurrences were outside the radiation field.
Takeaway
This study looked at how giving a cancer drug called Paclitaxel along with radiation helps women with a serious type of uterine cancer. It found that this combination can be helpful.
Methodology
Twenty-three high-risk endometrial cancer patients received Paclitaxel during radiotherapy and additional chemotherapy cycles afterward.
Limitations
The study involved a small number of patients and lacked a control group.
Participant Demographics
Patients were aged between 18 and 75 years, with various stages of high-risk endometrial cancer.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website